– Bader A., Winter R., Haas J., Tamussino K.: Where to look for the sentinel lymph node in cervical cancer. Am J Obstet Gynecol 2007; 197: 678.e1–678.e7
– Balleyguer C., Sala E., Cunha Da T., Bergman A., Brkljacic B., Danza F., Forstner R., Hamm B., Kubik-Huch R., Lopez C., Manfredi R., McHugo J., Oleaga L., Togashi K., Kinkel K.: Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol 2011; 21: 1102–1110
– Benedetti-Panici P., Greggi S., Colombo A. et al.: Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: Results from the Italian multicenter randomized study. J Clin Oncol 2001; 20: 179–188
– Bhatla N. et al.: FIGO Cancer Report 2018 – Cancer of the cervix uteri.
Int J Gynecol Obstet 2018; 143 (Suppl. 2): 22–36; doi: 10.1002/ijgo.12611
– Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M.: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377 (9783): 2085–92
– Diaz J.P., Sonoda Y., Leitao M.M., Zivanovic O., Brown C.L., Chi D.S., Barakat R.R., Abu-Rustum N.R.: Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecol Oncol 2008; 111 (2): 255–60
– Donovan B., Franklin N., Guy R., Grulich A.E., Regan D.G., Ali H., Wand H., Fairley C.K.: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11 (1): 39–44
– Fokdal L., Sturdza A., Mazeron R., Haie-Meder C., Tan L.T., Gillham C., Šegedin B., Jürgenliemk-Schultz I., Kirisits C., Hoskin P., Pötter R.: Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiother Oncol 2016; 120 (3): 434–40
– FUTURE II study Group: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861–1868
– Joura E., Leodolter S., Hernandez-Avila M. et al.: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693–1702
– Landoni F., Maneo A., Colombo A. et al.: Randomized study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350: 535–540
– Lee J., Lee K., Nam J. et al.: Prognostic factors in FIGO stage IB–IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: Results of a multi-center retrospective Korean study. Ann Oncol 2007; 19:3 21–326
– Mitchell D.G., Snyder B., Coakley F., Reinhold C., Thomas G., Amendola M., Schwartz L.H., Woodward P., Pannu H., Hricak H.: Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol 2006; 24: 5687–5694
– Muñoz N., Manalastas R. Jr., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., Clavel C., Luna J., Myers E., Hood S., Bautista O., Bryan J., Taddeo F.J., Esser M.T., Vuocolo S., Haupt R.M., Barr E., Saah A.: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 2009; 373 (9679): 1949–57
– NCCN Guidelines Cervical Cancer:
www.nccn.org/professionals/physician_gls/default.aspx#cervical
– Paavonen J., Jenkins D., Bosch F.X. et al.: Efficacy of a prophylactic adjuvant bivalent L1 virus-like vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet 2007; 369: 2161–2170
– Peters W.A., Liu P., Barrett R. et al.: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606–1613
– Petru E., Pasterk C., Reich O., Obermair A., Winter R., Breitenecker G.: Small-cell carcinoma of the uterus and the vagina: experience with ten patients. Archives of Gynecology and Obstetrics 2005; 271 (4): 316–319
– Podczaski E., Palombo C., Manetta A. et al.: Assessment of pretreatment laparotomy in patients with cervical carcinoma prior to radiotherapy. Gynecol Oncol 1989; 33: 71–75
– Ramirez P.T. et al.: Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med 2018; 379: 1895–1904
– Reich et al.: Gemeinsame Leitlinie der OEGGG, AGO, AGK und ÖGZ zur Diagnose und Therapie von zervikalen intraepithelialen Neoplasien sowie Vorgangsweise bei zytologischen Befunden mit eingeschränkter Qualität. Geburtsh Frauenheilk 2018; 78: 1232–1244
– Rose P., Bundy B., Watkins E. et al.: Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144–1153
– Rotman M., Sedlis A., Piedmonte M. et al.: A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: Follow-up of a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 2006; 65: 169–176
– S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, Langversion, 1.0, 2014, AWMF-Registernummer: 032/033OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html
– Sardi J., Sananes C., Giaroli A. et al.: Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol 1993; 49: 156–165
– Shingleton H., Soong S., Gelder M. et al.: Clinical and histopathological factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol 1989; 73: 1027–1034
– Small W., Winter K., Levenback C. et al.: Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive paraaortic or high common iliac lymph nodes: Results of arm 1 of RTOG 0116. Int J Radiat Oncol Biol Phys 2007; 68: 1081–1087
– Sturdza A., Hofmann S., Kranawetter M., Polterauer S., Grimm C., Krainer M., Kirisits C., Pötter R., Reinthaller A., Schwameis R.: Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy. Strahlenther Onkol 2017; 193 (12): 1056–1065
– Sturdza A., Pötter R., Fokdal L.U., Haie-Meder C., Tan L.T., Mazeron R., Petric P., Šegedin B., Jurgenliemk-Schulz I.M,. Nomden C., Gillham C.: Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 2016; 120 (3): 428–33
– Sturdza A., Viswanathan A., Erickson B., Yashar K., Bruggemman A., Feddock J., Klopp A., Beriwal S., Gaffney D., Han K., Kamrava M.: American Brachytherapy Society working group report on the patterns of care and a literature review of re-irradiation for gynecologic cancers. Brachytherapy 2020; 19 (2): 127–138
– Tewari K.S., Sill M.W., Long H.J. 3rd, Penson R.T., Huang H., Ramondetta L.M., Landrum L.M., Oaknin A., Reid T.J., Leitao M.M., Michael H.E., Monk B.J.: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370 (8): 734–43
– Uzan C., Souadka A., Gouy S., Debaere T., Duclos J., Lumbroso J., Haie-Meder C., Morice P.: Analysis of morbidity and clinical implications of laparoscopic para-aortic lymphadenectomy in a continuous series of 98 patients with advanced-stage cervical cancer and negative PET-CT imaging in the para-aortic area. Oncologist 2011; 16 (7): 1021–7
– Webb M., Symmonds R.: Site of recurrence of cervical cancer after radical hysterectomy. Am J Obstet Gynecol 1980; 138: 813–817
